{"id":"NCT03195491","sponsor":"Bristol-Myers Squibb","briefTitle":"A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia","officialTitle":"An Open Label, Safety Study of Participants With Non-Small Cell Lung Cancer Receiving Second-Line Nivolumab Monotherapy in Asia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-25","primaryCompletion":"2021-06-08","completion":"2021-06-08","firstPosted":"2017-06-22","resultsPosted":"2024-07-18","lastUpdate":"2024-07-18"},"enrollment":400,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lung Cancer","Non-Small Cell Lung Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab","otherNames":["Opdivo","BMS-936558"]}],"arms":[{"label":"Monotherapy","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to investigate the safety of patients in Asia with Non-Small Cell Lung Cancer (NSCLC)who are treated with Nivolumab monotherapy as a second line or third line treatment.","primaryOutcome":{"measure":"Number of Non-HBV Participants Experiencing High Grade Treatment-Related Select Adverse Events","timeFrame":"From first dose up to 100 days post dose, up to approximately 36 months","effectByArm":[{"arm":"Non-HBV Participants","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":30,"countries":["China","Thailand"]},"refs":{"pmids":[],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":157,"n":383},"commonTop":["Anaemia","Decreased appetite","Cough","Pyrexia","Weight decreased"]}}